2023 – 2024 ASKP3 Expert Faculty
The ASKP3 Expert Faculty members are developing a roadmap for the future of ketamine and emerging treatments that is rooted in research, education, and standards of best practice. Expert Faculty members also serve as an extension of the ASKP3 Board of Directors, providing input and guidance on practice issues in the ketamine field, as needed.
Annually, the ASKP3 Board of Directors reviews the list of Faculty and makes adjustments to ensure that the faculty represents our intradisciplinary community. If you are interested in joining the ASKP3 Expert Faculty, please email ASKP3 Headquarters at firstname.lastname@example.org.
Julane Andries, LMFT
Julane Andries is a practicing psychotherapist in Marin County, CA. She worked in acute care medicine before becoming a marriage family therapist. She is an investigator in the MAPS Phase 3 study using MDMA-assisted psychotherapy for severe PTSD in San Francisco. She was the principal co-therapist for the MAPS-sponsored, Phase 2 MDMA-assisted psychotherapy study for individuals suffering from anxiety with life-threatening illness. She has been a pioneer in the development of Ketamine Assisted Psychotherapy
Her work is unique and is creative to the psychotherapy process using this medicine. She, along with others on their team, treats patients with treatment resistant depression, first line depression, anxiety and PTSD, as well as those seeking transformation.
She and Dr. Wolfson have founded a non-profit, Ketamine Research Foundation, whose mission is to provide training for practitioners, collect data to track outcomes with ketamine therapy, starting a new protocol for using KAP for those diagnosed with a life-threatening illness, and those in palliative and hospice care, research in lactating women and ketamine for post-partum depression, ketamine for PMS and other projects. Julane is also co-founder of the Ketamine Training Center and helps lead trainings across the country teaching practitioners in the skills used in KAP.
Michael Banov, MD
Dr Michael Banov is Medical Director of Psych Atlanta, Psych Atlanta Treatment Resistant Depression Program, and Psych Atlanta Research Center, which has offices in Marietta and Roswell, Georgia. He is also a Clinical Assistant Professor in the Department of Psychiatry at the Medical College of Georgia in Augusta, Georgia. He is Medical Director and President of Psychsource, LLC, a not-for-profit that provides mental health information to the community.
Dr Banov earned his medical degree from Emory University School of Medicine in Atlanta, Georgia. He completed a clinical fellowship in adult psychiatry at Harvard Medical School in Boston, Massachusetts. He also completed a residency where he was Chief Resident in the psychotic disorders program at Harvard Medical School. Dr Banov is board certified by the American Board of Psychiatry and Neurology and is also certified in adolescent psychiatry and addiction psychiatry. He has given numerous presentations at national academic and medical conferences on managing and caring for patients with psychiatric disorders.
He is Principal Investigator on several active clinical trials studying the safety and effects of different therapeutics to treat mental health disorders, such as anxiety, depression, and attention-deficit/hyperactivity disorder. He has been published in several peer-reviewed journals, such as CNS Spectrums and Brain Stimulation. He is a distinguished fellow in the American Psychiatric Association and a fellow in the Academy of Physicians in Clinical Research. He has been the medical director of Psych Atlanta Ketamine, Spravato, and TMS treatment center since its inception seven years ago.
Michael Bloch, MD, MS
Michael H. Bloch, M.D., M.S., graduated from Yale School of Medicine and completed his child and adult psychiatry training at Yale. His research interests focus on studying Tourette syndrome (TS), obsessive-compulsive disorder (OCD) and trichotillomania (TTM) across the lifespan and developing better pharmacological treatments for children with depression, anxiety, and ADHD. His research focuses on developing better treatments for children and adults with these conditions particularly through clinical trials and meta-analysis.
Dr. Bloch is also the associate training director of the Child Study Center's innovative psychiatry residency program. The Solnit Integrated Program provides psychiatrists-in-training with the opportunity to integrate general, child, and research psychiatry across all stages of their careers and will be a major pathway by which the next generation of academic leaders in child psychiatry are developed
Carl Bonnett, MD
Dr. Carl J. Bonnett, MD, is the founder and Chief Medical Officer of Klarisana. Dr. Bonnett has been active in the field of Psychedelic Medicine since he founded Klarisana in 2015. Currently Klarisana operates five centers in Colorado and Texas. Last year Klarisana performed nearly 20,000 ketamine treatments.
Dr. Bonnett is also one of the founding board members of ASKP3. Dr. Bonnett completed his residency in 2005 at the Denver Health Medical Center Residency in Emergency Medicine. He then completed a fellowship in EMS and Disaster Medicine at Denver Health. He also retired from the Army National Guard in 2015 (LTC) with twenty years of service and four deployments to the Middle East. In 2007 Dr. Bonnett was awarded the Combat Medical Badge for providing care under fire while deployed with the 41st Brigade Combat Team in Afghanistan.
The impetus for him to enter the field of psychedelic medicine was the alarmingly high Veteran suicide rate. He recognized the incredible promise that ketamine and other medications could have for treating PTSD by leveraging a non-ordinary state of consciousness. Dr. Bonnett and his team at Klarisana have published three original research papers so far in the field of ketamine treatment for mental health conditions.
Glen Brooks, MD
Dr. Brooks is generally recognized as the nation’s leading practitioner of ketamine infusion therapy and chronic pain. He is a board-certified anesthesiologist, completed his training at Harvard’s Brigham and Women’s Hospital and taught at Yale University School of Medicine.
In 2012, Dr. Brooks founded NY Ketamine Infusions in New York City as one of the world’s first therapy centers dedicated exclusively to providing this breakthrough therapy.
Lori Calabrese, MD
With over 20 years of experience, Lori Calabrese, MD, is a graduate of The Johns Hopkins University School of Medicine and completed her residency training through Harvard Medical School at Massachusetts General Hospital, consistently recognized as the finest program in the country.
She has served as clinical faculty at both Harvard Medical School and Yale School of Medicine and is called “a doctor’s doctor,” as so many physicians and their families rely on her expertise and treatments.
Dr. Calabrese is a specialist in interventional psychiatry, ketamine treatment, and metabolic psychiatry, and incorporates the newest scientific information regarding ketamine, MDMA and other psychedelic compounds, brain health and mitochondrial energy science, genetic testing, inflammation and the brain-gut microbiome connection into the care of her patients.
Angelo De Gioannis, MD
Dr. Angelo De Gioannis is a consultant psychiatrist from Brisbane. He is in full-time private practice and specializes in the pharmacological and psychological management of treatment-resistant anxiety and depression. Since 2012, he has specialized in the use of home-based oral ketamine treatment for mood disorders and chronic pain syndromes.
Lara Edinger, DO
Dr. Lara Edinger specializes in the treatment of chronic neuropathic and musculoskeletal pain disorders. She is board certified in Neurology and Pain Medicine and is an assistant clinical professor at the UCLA Department of Neurology.
While her focus is mainly on Complex Regional Pain Syndrome (CRPS) she has particular interests in post traumatic headache, pelvic pain, peripheral neuropathy, fibromyalgia, mast cell activation, and phantom limb syndrome.
Dr. Edinger has provided expert services in a variety of legal cases involving:
- Complex Regional Pain Syndrome
- Chronic post traumatic headache
- Traumatic brain injury
- Musculoskeletal pain disorders resulting from trauma
- Degree of impairment and disability caused by pain
- Evaluation of costs associated with treatment
- Providing opinions on life care planning
David Feifel, MD, PhD
Dr. David Feifel earned a Bachelor of Science, Master’s Degree, MD, and a PhD(Neurobiology) from the University of Toronto, Canada. After completing an internship in Internal Medicine, Dr. Feifel completed a Psychiatry residency at the University of California, San Diego, serving as outpatient Chief Resident in his final year.
He was then recruited to join UCSD’s School of Medicine as a faculty member and rose to rank of full Professor in the Department of Psychiatry and in the Neuroscience graduate program.
At UCSD Dr. Feifel was Director of the Neuropsychiatry and Behavioral Medicine Program, was the founder and Director of the UCSD Adult ADHD program, and created the Department of Psychiatry’s Center for Advanced Treatment where he introduced several novel treatments such as Transcranial Magnetic Stimulation (TMS) and Ketamine Therapy. He was one of the first providers in the country to utilize these treatments.
Tiago Gil, MD
Dr. Tiago Gil, MD, is a board-certified anesthesiologist with a focus on ketamine's applications for mood disorders.
After years of experience in operating rooms and emergency medicine, he established a Ketamine Clinic in São Paulo, Brazil in 2017, where he personally administers a significant number of infusions.
In 2019, Dr. Gil joined the research group at Universidade de São Paulo (USP), concentrating on mood disorders. His work is guided by ethics and evidence-based medicine, aligning his practice with the best available scientific knowledge. Dr. Gil is on the verge of publishing the first real-world data on IV esketamine outcomes in the Brazilian population. He remains committed to expanding his expertise in anesthetics with mood-altering properties and seeks collaborative partnerships to further professionalize his work. With a dedication to professionalism and science-based practice, Dr. Tiago Gil, MD, contributes to the field of anesthesiology and psychiatry by exploring innovative treatments for mood disorders.
Veronika Gold, LMFT
Veronika is a lead trainer in the Polaris Insight Training Program. She is a marriage and family therapist who specializes in the treatment of trauma. She is a Certified Somatic Experiencing Practitioner, Certified EMDR therapist, Consultant, and Facilitator, and Realization Process Teacher.
She has undergone multiple training in psychedelic-assisted psychotherapy, including advanced training through the Ketamine Training Center and Kriya Institute, and MDMA-Assisted Therapy Training through MAPS, 5-meo Training through Fluence. She was a Sub-Investigator and Co-therapist, and currently is a consultant and an educator on the MAPS MDMA-Assisted Therapy Clinical Trials for the treatment of PTSD.
Brandon Kitay, MD, PhD
Dr. Brandon Kitay is an Assistant Professor of Psychiatry and Behavioral Sciences at the Emory School of Medicine, Director of Behavioral Health Integration for Emory Healthcare, and an "Interventional Psychiatrist," with clinical and research expertise in the application of electroconvulsive therapy, ketamine, and esketamine therapies for treatment refractory mood disorders.
His research efforts include developing structural interventions to overcome access barriers for therapies like ketamine/esketamine within health systems.
Dr. Kitay received his BS, MD, and PhD from the University of Miami Miller School of Medicine (FL) and completed residency in adult psychiatry through the Neuroscience Research Training Program (NRTP) at the Yale School of Medicine followed by a research fellowship at the Yale Depression Research Program (YDRP). In June 2020, he joined the faculty at the Emory School of Medicine.
Sam Ko, MD
Samuel Ko, MD, MBA, is the founder and medical director of Reset Ketamine (www.resetketamine.com) in Palm Springs, California. His clinic has been featured in Vice, White Coat Investor, Gizmodo, Independent, and NBC Palm Springs.
He is committed to providing an innovative and rapid treatment for depression, anxiety, PTSD, and chronic pain so that patients can go back to living a whole, healthy life.
Dr. Ko is a Board Certified Emergency Physician, a Fellow of the American College of Emergency Physicians, Fellow of the American Academy of Emergency Medicine, and a member of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners. He is a graduate of University of Rochester’s combined MD/MBA program and has additional training from Co-Active Training Institute (CTI), Reiki Master, Neuro-linguistic programming, and Time Line Therapy. His most recent project is an online course teaching other clinicians how to start their own ketamine private practice www.ketaminestartup.com
Robert Krochmal, MD
Dr. Rob Krochmal has been practicing medicine for close to 20 years, and maintains three Board Certifications- in Family Medicine, Nutrition, and in Integrative and Holistic Medicine. He draws his inspiration from the healing power of nature, and is passionate about the link between individual health and the health of our environment. He is particularly passionate about finding root causes and helping patients understand their bodies in order to empower themselves to heal.
Carlene MacMillan, MD
Carlene MacMillan, MD, a Harvard-trained double board-certified adult and child psychiatrist, is the Chief Medical Officer at Osmind. Osmind is a technology platform that enables clinicians to deliver breakthrough mental health treatments including ketamine and transcranial magnetic stimulation.
Dr.MacMillan serves on the Board of the Ketamine Taskforce for Access to Safe Care and Insurance Coverage as a Vice President. She is on the Board of Directors of the Clinical TMS Society and the Co-Chair of the Insurance Committee. She is the Co-Chair of the American Academy of Child and Adolescent Psychiatry Consumer Issues Committee. She advocates for evidence-based treatments to be reimbursed by payers and is a staunch supporter of the incorporation of measurement-based care into the practice of all mental health professionals.
Dr.MacMillan participates in multiple additional national and local committees and workgroups on behalf of the American Psychiatric Association dedicated to these initiatives. She practices clinically as the co-founder of Fermata, an interventional psychiatric group practice and clinical trial site for rapid acting mental health treatments in New York City.
Michael Mantz, MD
Michael Mantz, MD, MH, is a board-certified physician by the American Board of Psychiatry & Neurology. He graduated from the University of Pittsburgh School of Medicine in 2009 and he holds a master’s degree in Herbal Medicine.
Dr. Mantz has received additional mentorship and training in both functional and integrative medicine. During his psychiatric residency training at UC Irvine, Dr. Mantz completed several courses on psychodynamics, hypnosis, and mindfulness-based psychotherapies.
Dr. Mantz and his wife Dr. Kim Le started a private practice in Santa Barbara in 2015 – Santa Barbara Integrative Psychiatry. In 2019, he and his wife began treating patients using Ketamine-assisted Therapy (KAT).
Dr. Mantz gives presentations and leads groups on functional and integrative psychiatry. His focus is on improving brain function using a combination of modern clinical medicine, neuroscience, and psychotherapy weaved together and blended with ancient healing wisdom practices.
Dr. Mantz has been on two podcasts and gave a presentation on ketamine recently:
Audio: Fear Me Out Podcast, Episode 82: Dr. Mantz – Ketamine Therapy
Video: Sapio Podcast, Episode 12: Reprogramming your Brain with Ketamine
His latest Grand Rounds Presentation: Ketamine: The Good, The Bad, and the Great Potential:
Dr. L. Alison McInnes is Vice President, Scientific Affairs at Osmind. She is a nationally recognized expert in psychiatry and mood and anxiety disorders, having specialized in treating refractory disease for over a decade. She is additionally an expert in ketamine treatment and psychedelic medicine.
Dr. McInnes received her bachelor’s and master’s degrees from Stanford University and her MD from Columbia University graduating with honors (Alpha Omega Alpha). She completed residency at UCSF and received both a VA Research Fellowship and Howard Hughes Physician Research Fellowship at that time. She continued to do research and became an Associate Professor of Psychiatry at Mount Sinai School of Medicine where she ran a NIMH-funded lab studying the genetics of behavioral disorders. She then went on to found and direct a multi-site ketamine therapy program at Kaiser Permanente in Northern California before coming to Osmind.
She is a member of the American College of Neuropsychopharmacology and has authored two important papers describing outcomes of ketamine infusion therapy in the largest real-world data sets examined to date. Other memberships include ASKP3, APPA, and APA. In her current clinical practice, she focuses on difficult-to-treat mood disorders and complex cases.
Rupert McShane, MD, FRCPsych
Rupert McShane leads the Interventional Psychiatry Service (ECT, TMS and ketamine) at Oxford Health NHS Trust. An Old Age Psychiatrist by training, he was previously Coordinating Editor for the Cochrane Dementia Group and now runs a ward and a memory clinic. Following a small NIHR study of ketamine in resistant depression, he established a ketamine clinic at Oxford Health https://www.oxfordhealth.nhs.uk/ketamine/. This includes both self-pay and NHS-funded streams. This now includes online group ‘preparation’ and ‘integration’ sessions. His team, which includes three out-of-programme clinical fellows who spend a year in the IPS, also runs an international ketamine journal club (2nd and 4th Tuesdays at 5.30pm), a consultant peer group for those interested in ketamine or TMS, and a biannual conference (https://www.ketamineconference.org/). He is particularly interested in what it would take to scale an effective treatment which costs £0.70 a dose for safe NHS use.
Brittany O’Brien, PhD
Brittany O’Brien, PhD, is an Associate Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. She received her doctorate in clinical psychology from The New School for Social Research and completed her postdoctoral training at Baylor College of Medicine.
Dr. O’Brien is an expert in evidence-based behavioral interventions for mood, anxiety, and trauma-related disorders with risk of suicide. She has served as co-investigator on multiple state, industry, and foundation sponsored clinical research studies investigating the efficacy and effectiveness of ketamine, psilocybin, and other glutamatergic modulators.
Dr O’Brien has a specific interest in the effectiveness of ketamine as a treatment for psychiatric disorders and factors that enhance or limit treatment response. Her work in this area has been presented and published on the national and international level. In addition to her clinical work and research, Dr. O’Brien is committed to training the next generation of clinical psychologists. Currently, she oversees the Mood & Trauma Related Disorders pre-doctoral training internship in the Psychology Division at Baylor College of Medicine.
Patrick Oliver, MD
Patrick Oliver, MD, is an experienced ketamine infusion specialist serving patients at MindPeace Clinics in Richmond, Arlington, and Norfolk, Virginia.
Dr. Oliver started his career as a business process consultant, later realizing his true passion was becoming a physician. He earned his medical degree from the Medical College of Virginia at the Virginia Commonwealth University in Richmond, Virginia, and completed his residency in emergency medicine at St. Luke’s Hospital in Bethlehem, Pennsylvania. He is certified by the American Board of Emergency Medicine and is licensed to practice medicine in Virginia.
Dr. Oliver worked for several emergency departments throughout the Commonwealth of Virginia. He currently teaches medical students and emergency medicine residents in addition to serving as Medical Director for MindPeace Clinics.
Megan Oxley, MD
Dr. Megan Oxley is the founder and medical director of Michigan Progressive Health. A Board Certified Emergency Medicine physician, Dr. Oxley graduated from prestigious Wayne State University in 2009. She completed her residency training in Emergency Medicine in Detroit, serving the inner city. She spent a decade working in emergency departments in Michigan and Maryland.
While researching options to help a family member with treatment resistant depression, she discovered the immense benefit that ketamine can have in chronic mood and pain conditions. Dedicated to providing this service to as many as possible, she established Michigan Progressive Health, an integrative ketamine infusion clinic in Royal Oak Michigan. Dr. Oxley has been providing ketamine infusions for over four years.
She is a founding Board member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners. One of Dr. Oxley’s passions is to educate the public on the use of ketamine in treating mood disorders and other ailments. She has organized the ASKP3 conferences for the last three years and has been a speaker for the previous two ASKP3 conferences.
She has lectured at several major universities in Michigan to both medical students and psychiatry residents to help expand education and awareness of this rapidly evolving therapeutic modality. In addition, Dr. Oxley is currently participating in a year-long integrative psychiatry fellowship with the Integrative Psychiatry Institute. Dr. Oxley has a special interest in using ketamine and future psychedelic medicines to help patients reduce their need for conventional psychiatric medications and improve their overall health.
Jonathan Reitman, MD
Dr. Jonathan Ezra Reitman, MD, is a health care provider primarily located in Beverly Hills, CA, with other offices in Los Angeles, CA, and Culver City, CA. He has 26 years of experience. His specialties include Addiction Medicine, Internal Medicine, and Critical Care Medicine. Dr. Reitman is affiliated with Southern California Hospital at Culver City. He speaks Spanish and English.
Steve Rosonke, MD
Dr. Rosonke founded Rainfall Medicine in 2018 to dedicate himself to providing effective treatment for mental illness, trauma, and addiction in a safe, peaceful, and inviting setting. In addition to his rigorous emergency medicine and critical care education, which was followed by years of direct clinical experience with ketamine for various applications, Dr. Rosonke was a participant in the first ever training cohort for ketamine-assisted psychotherapy through the Ketamine Training Center. He has since become an educator for the Ketamine Training Center, instructing other professionals on the safe and effective use of ketamine for mental illness.
Dr. Rosonke also has partnered with Polaris Insight Center and leads many ketamine trainings both online and in-person. Additionally, Dr. Rosonke and the Rainfall Clinic have been accepted into the training program for MDMA therapy through the Multidisciplinary Association for Psychedelic Studies (MAPS). Dr. Rosonke also works as a consultant for training therapists and helping providers set up new practices. He is also
Tatiana Santini, MA, RP, RCC, SEP
Tatiana is a Psychotherapist, experienced Psychedelic Assisted Therapist and a Ketamine Assisted Therapist, currently living and working in Vancouver, BC (Canada). She is a trauma therapist, educator, and a doctoral student in counselling and psychotherapy.
Tatiana has extensive experience working with patient populations affected by complex trauma, addictions, and chronic pain. Tatiana's greatest interests and hopes are to contribute to education, and to help create best ethical and clinical standards and practices when working with non-ordinary states. Tatiana is a social justice advocate, committed to creating equity in accessing resources, in particular treatment for substance use disorders for individuals from underrepresented groups, and communities who have been historically marginalized.
Harvey Schwartz, PhD
Dr. Harvey Schwartz is a licensed clinical psychologist specializing in treating complex PTSD, dissociative disorders, as well as patients with spiritual and therapy-related trauma, with extensive experience supervising, consulting, and mentoring psychotherapists. He is a co-founder and training director of Polaris Insight Center, and works for MAPS as therapist/researcher, educator, training consultant, and mentor supervisor. He synthesizes relational psychoanalytic and transpersonal clinical approaches, and works on advancing the theory and practice of countertransference awareness and integration in psychedelic assisted psychotherapies.
Scott Shannon, MD
Scott has been a student of consciousness since his thesis on that topic at the University of Arizona in the 1970s. Following medical school, MDMA assisted psychotherapy became part of his practice before this medicine was scheduled in 1985. He completed a psychiatry residency at a Columbia program in New York. Scott also completed a child/adolescent psychiatry fellowship at the University of New Mexico.
Scott has published four books on holistic and integrative mental health including the first textbook for this field in 2001. He founded Wholeness Center, the largest integrative mental health center in the US, in 2010. Scott is a past president of two national medical organizations. He serves as a site Principal Investigator and therapist for the Phase III trial of MDMA assisted psychotherapy for PTSD. Scott has also published numerous articles about cannabidiol in mental health.
He is currently involved with 5-MEO-DMT and LSD research. Scott co-founded the Psychedelic Research and Training Institute (PRATI) to train professionals in ketamine-assisted psychotherapy. Scott served as the initial CEO for the Board of Psychedelic Medicine and Therapies in 2021. He lectures all over the world to professional groups interested in a paradigm shifting perspective about transformative care.
Eric Sienknecht, PsyD
Eric Sienknecht, PsyD, is a Co-Founder, Clinical Psychologist, and Lead Trainer at Polaris Insight Center, a ketamine-assisted psychotherapy clinic and training center in San Francisco. He is also a Supervisor and Educator in the MDMA-AT program with MAPS/MPBC. His professional interests include relational psychoanalysis, consciousness research, and music and psychedelics.
Lowan Stewart, MD
Dr. Stewart is an Emergency Physician, Fellow of the American College of Emergency Medicine, practicing since 2003 in the US and in Norway. He trained at the University of New Mexico School of medicine and Oregon Health and Sciences University. He was an associate clinical professor at OHSU. He worked with the Norwegian Society of Emergency Medicine to bring the specialty of emergency medicine (AMM) to Norway.
He was a founder of Santa Fe Ketamine (now Insight) in New Mexico - the first in the state in 2016, Axon Clinic - the first in Norway in 2018, and the first public ketamine treatment unit in Scandinavia in 2020.
His current research interests include using novel psychoactive medications in the treatment of mood disorders and addiction. He is the medical advisor at PsykForsk, DPS Nordre Østfold and the site physician for international clinical trials on psilocybin, MDMA and ketamine. He is the current academic medical advisor to the public ketamine treatment center at DPS Moss, previous Regional Director of the Nordics for Awakn Life Sciences, and now the Medical Director of Axon Clinics. Dr. Stewart is the co-founder of the Norwegian Association for Psychedelic Science and serves as an associate editor for the Journal of Psychedelic Studies.
Sunny Strasburg, LMFT
Sunny Strasburg, LMFT, is certified in Psychedelic Assisted Psychotherapy by the California Institute of Integral Studies. She has been trained in psilocybin therapy by Compass Pathways and Synthesis. Mrs Strasburg was trained in MDMA by Michael and Annie Mithoefer through MAPS and Ketamine Assisted Psychotherapy by the Ketamine Training Center.
Sunny works with Dr. Phil Wolfson, author of The Ketamine Papers. She is also a Lead Trainer at the Ketamine Training Center, and hosts KAP retreats. Mrs Strasburg serves as a consultant for licensed practitioners. Sunny has been interviewed and given keynote presentations for the Trauma Research Foundation, EMDRIA Worldwide, The Seminar, ShrinkRap Radio, and the K Dome.
Gita Vaid, MD
Gita Vaid is a Board Certified Psychiatrist and psychoanalyst practicing in New York City. She serves as a lead instructor at The Ketamine Training Center with Dr. Phil Wolfson.
Dr. Vaid serves as the International Course Director for Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies and the Director of Psychedelic Awareness at The Chopra Foundation. She is a co-founder of the Center for Natural Intelligence — a multidisciplinary laboratory dedicated to psychedelic psychotherapy innovation.
Laura Wiginton, LCSW
Laura Wiginton is a Licensed Clinical Social Worker and a psychotherapist in private practice in Houston, Texas. Her current clinical practice is focused on the use of Ketamine Assisted Psychotherapy in the treatment of mood disorders and trauma.
Laura received her bachelor’s degree from Rice University and her master’s degree from the University of Texas at Austin. She is a member of the Ketamine Psychotherapy Associates (KPA) and serves as the liaison for ASKP3’s Therapist Advisory Panel to the ASKP3 Board of Directors. She is involved with and has served on the Board of Directors for the Houston Eating Disorder Specialists and the Houston Group Psychotherapy Society.
In addition to her work with ketamine, Laura also trained in MDMA Assisted Psychotherapy with the Multidisciplinary Association for Psychedelic Studies (MAPS). She is always learning and growing as a clinician, and brings the full force of her creativity, intelligence, and love to the work that she does.
Jennifer Winegarden, DO
Jennifer Winegarden is Board-certified in Family Medicine, Board-certified in Hospice & Palliative Medicine, and has a Masters of Science in Pain Medicine.
Experience includes service as a full-time hospice and palliative physician for 12 years with executive leadership and strategic planning involvement as well as being anationally-recognized speaker in pain and palliative medicine.
Stefany Wolfsohn, MD
Dr. Stefany Wolfsohn is a board-certified Anesthesiologist and a lifelong resident of Ventura County.
In September 2017, Dr. Wolfsohn founded the Ventura Center for Advanced Therapeutics where she has been able to offer cutting-edge ketamine-based therapies and IV therapy solutions for treatment-resistant mental health and chronic pain conditions. The practice combines a holistic, individualized approach that utilizes ketamine therapy together with other complementary interventions to bring relief to patients who have found limited success with other treatment modalities. Collaborative care involving licensed mental health providers and/or coaches with additional training in these therapies is encouraged to provide appropriate psychological support before, during and after each treatment experience.
Dr. Wolfsohn has worked across a broad spectrum of settings, including both in-hospital and outpatient surgery centers. A Diplomate of the American Board of Anesthesiology, Dr. Wolfsohn has over a decade of experience providing anesthesia services and perioperative care to patients in large interventional pain practice. In this setting, she has specialized in treatment-resistant chronic pain syndromes.
Dr. Wolfsohn has obtained additional mental health, trauma, and psychedelic medicine training from Vital, a 12-month program through Psychedelics Today. She is currently pursuing a master’s in clinical counseling at Alliant International University and is expected to graduate in 2025.
She is a member of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3), the American Society of Anesthesiologists, APPA and APA. Dr. Wolfsohn has been safely administering ketamine for treatment-resistant conditions since 2007 and has a special interest in helping groups and individuals with complex mental health and pain conditions.
Jeffrey Zabinski, MD, MSW, MA
Jeffrey Zabinski, MD, MSW, MA, is an Assistant Professor of Psychiatry at Columbia University Irving Medical Center, where he is the Program Lead for ketamine under the interventional psychiatry services. He specializes in psychotherapy and psychopharmacology for patients with difficult to treat and medically complex psychiatric illness.
Dr. Zabinski's unique multidisciplinary background started with undergraduate studies in biomedical engineering, followed by an MSW and an MA in bioethics. After medical school, he completed adult psychiatry residency at Johns Hopkins where he served as a Chief Resident, then a consultation-liaison psychiatry fellowship at NYU.
Since joining Columbia in 2020, he has helped in the launch of the intranasal esketamine and IV ketamine clinical services. He has active interests in neuropsychiatry, delirium, medical ethics, psychedelics, and interventional psychiatry. Dr. Zabinski believes in the safe, thoughtful expansion of access to a broad array of novel evidence-based treatments - and getting those treatments to patients who need them the most. He is optimistic about the role of ketamine and ASKP3, and hopes to bring his expertise to the ongoing dialogue about the future of ketamine in clinical care, research, and education.